Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...
Tallennettuna:
Päätekijät: | , , , , , , , , , |
---|---|
Aineistotyyppi: | Artikkeli |
Kieli: | englanti |
Julkaistu: |
Philipps-Universität Marburg
2022
|
Aiheet: | |
Linkit: | PDF-kokoteksti |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
PDF-kokotekstiHyllypaikka: |
urn:nbn:de:hebis:04-es2023-00588 |
---|---|
Julkaisupäivä: |
2023-05-16 |
Lähde: |
Erstveröffentlichung: Otte, K.; Zhao, K.; Braun, M.; Neubauer, A.; Raifer, H.; Helmprobst, F.; Barrera, F.O.; Nimsky, C.; Bartsch, J.W.; Rusch, T. Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022, 10, 2145. https://doi.org/10.3390/biomedicines10092145 |
Downloads: |
21 (2024), 44 (2023) |
Lizenz: |
https://creativecommons.org/licenses/by/4.0 |
Linkki aineistoon: |
https://archiv.ub.uni-marburg.de/es/2023/0058 https://doi.org/10.3390/biomedicines10092145 |